<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131884</url>
  </required_header>
  <id_info>
    <org_study_id>U of R 29563</org_study_id>
    <nct_id>NCT01131884</nct_id>
  </id_info>
  <brief_title>Pilot Study of Fosamax in Spinal Cord Injury</brief_title>
  <official_title>Double Blind Placebo Controlled Trial to Evaluate Preservation of Bone Mineral Density of the Hip and Distal Femur by Biphosphate Therapy (Fosamax) Following Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in
      acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry
      (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months
      and be required to take oral fosamax versus placebo weekly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project was funded on August 13, 2009 and was awarded to one of our trainees, Dr. Matthew
      Abraham, a PGY3 in our program and our IRB approval was obtained with much time and effort on
      February 24, 2010. We followed the protocol and so far we recruited just one patient on
      September 19, 2011 who completed the study but we encountered with many unexpected obstacles
      to recruit any more patients to the study. The main obstacle was that the spine surgeons'
      refusal to start the study drug for months after surgery for fear of complications with wound
      healing. Secondly, the few appropriate and eligible patients we tried to recruit declined to
      participate.

      We were unable to recruit any more patients to this study and hence the study was closed.

      The one patient that was recruited completed the study. Since it is only one subject in the
      study, no conclusions can be drawn.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Only 1 participant enrolled since the beginning of this study
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>1 year after enrollment</time_frame>
    <description>Whether or not Fosamax increases bone mineral density at the hip and distal femur in spinal cord injury induced osteoporosis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Fosamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosamax at 70 mgs q weekly by mouth for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind study using Fosamax versus placebo. Placebo is an inactive drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamax</intervention_name>
    <description>70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year</description>
    <arm_group_label>Fosamax</arm_group_label>
    <other_name>Alendronate sodiuum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.</description>
    <arm_group_label>Placebo Sugar Pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury
             Association (ASIA) B Spinal Cord Injury

        Exclusion Criteria:

          -  History of hypersensitivity to alendronate or other bisphosphonates

          -  esophageal abnormality

          -  inability to sit/stand upright for 30 minutes

          -  creatinine clearance less than 35 milliliters/minute

          -  hypothyroidism

          -  malignancy

          -  pregnancy

          -  prolonged steroid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanakadurga R Poduri, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Physical Medicine and Rehabilitation</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>September 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2013</results_first_posted>
  <last_update_submitted>December 25, 2015</last_update_submitted>
  <last_update_submitted_qc>December 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>K. R Poduri</investigator_full_name>
    <investigator_title>Chair of Department of PM&amp;R</investigator_title>
  </responsible_party>
  <keyword>ASIA A or ASIA B Spinal Cord Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A 57 year old T4 paraplegic was recruited while he was going through rehabilitation at Strong Memorial Hospital inpatient rehab unit. This patient was recruited and signed consent on 8/05/2011.He underwent lab work and dexa scan per protocol and on completion of the investigation on September 19, 2011 he started the treatment(Fosamax vs. Placebo).</recruitment_details>
      <pre_assignment_details>Recruitment beyond one patient was not possible due to A. surgeons unwillingness to initiate Fosomax treatment for fear of wound healing. B. The eligible patients' reluctance to participate in the study. C. Given the length of time it took to enroll one, it is not feasible to complete the study with required # in the protocol in the next few years</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fosamax</title>
          <description>Fosamax : 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year</description>
        </group>
        <group group_id="P2">
          <title>Placebo Sugar Pill</title>
          <description>Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
Placebo : Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fosamax</title>
          <description>Fosamax : 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year</description>
        </group>
        <group group_id="B2">
          <title>Placebo Sugar Pill</title>
          <description>Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
Placebo : Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="0"/>
                    <measurement group_id="B3" value="58" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density</title>
        <description>Whether or not Fosamax increases bone mineral density at the hip and distal femur in spinal cord injury induced osteoporosis</description>
        <time_frame>1 year after enrollment</time_frame>
        <population>No analysis performed as there was only one patient who participated in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Fosamax</title>
            <description>Fosamax : 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sugar Pill</title>
            <description>Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
Placebo : Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>Whether or not Fosamax increases bone mineral density at the hip and distal femur in spinal cord injury induced osteoporosis</description>
          <population>No analysis performed as there was only one patient who participated in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fosamax</title>
          <description>Fosamax : 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year</description>
        </group>
        <group group_id="E2">
          <title>Placebo Sugar Pill</title>
          <description>Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
Placebo : Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>K.Rao Poduri, M.D., Chair of Physical Medicine &amp; Rehab</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-6978</phone>
      <email>kr_poduri@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

